Table 1.

Clinical–pathologic characteristics of patients

All patients (n = 125) (%)Patients with LKB1 data (n = 98) (%)
Gender
 Female40 (32.0)30 (30.6)
 Male85 (68.0)68 (69.4)
Age at diagnosis
 Median (IQ range)64.0 (58.0–71.0)64.0 (56.0–70.0)
 ≤7090 (72.0)74 (75.5)
 >7035 (28.0)24 (24.5)
Histology
 Adenocarcinoma98 (78.4)76 (77.5)
 Squamous cell carcinoma15 (12.0)10 (10.2)
 Large cell carcinoma4 (3.2)4 (4.1)
 Other/NOS8 (6.4)8 (8.2)
PS (ECOG)
 046 (36.8)36 (36.7)
 173 (58.4)56 (57.1)
 26 (4.8)6 (6.1)
Smoking status
 Current54 (43.2)40 (40.8)
 Former51 (40.8)42 (42.9)
 Never20 (16.0)16 (16.3)
First-line treatment
 Platinum doublet plus bevacizumab42 (33.6)39 (39.8)
  Cisplatin-gemcitabine21 (50.0)19 (48.7)
  Carboplatin-paclitaxel15 (35.7)14 (35.9)
  Cisplatin-pemetrexed5 (11.9)5 (12.8)
  Carboplatin-gemcitabine1 (2.4)1 (2.6)
 Platinum-doublet83 (66.4)59 (60.2)
  Carboplatin/gemcitabine24 (28.9)18 (30.5)
  Cisplatin-gemcitabine5 (6.0)4 (6.8)
  Carboplatin/pemetrexed41 (49.4)28 (47.4)
  Cisplatin/pemetrexed12 (14.4)8 (13.5)
  Carboplatin/paclitaxel1 (1.2)1 (1.7)